DIFFERENTIAL PHOSPHORYLATION OF ANTI-HIV AGENTS, AZT, DDC, AND DDI, IN PBM

用于测试抗病毒药物的快速、可靠和灵敏的测定系统 潜在药物的活性对于开发 艾滋病的抗病毒治疗现在已经开发了多种体外测定系统， 这些分析系统应该进一步加速 确定新的抗逆转录病毒药物。 但若干 变量或因素影响体外抗病毒药物的结果 试验. 抗病毒数据可能会因靶细胞的不同而有很大差异 就业。 病毒剂量、病毒株、药物添加时间、持续时间 文化和使用的终点也会显著影响 抗病毒数据。 人外周血单个核细胞（PBM）已被频繁使用， 作为用植物血凝素（PHA）刺激后的靶细胞， 研究各种药物对艾滋病病毒的作用。 PHA刺激的PBM （PHA-PBM）可以提供接近体内情况的环境， 因此可以作为最合适的靶细胞之一， 抗病毒测试 然而，人们还不太清楚， 在PHA-PBM中评估的HIV-1对药物的敏感性与 艾滋病患者的病毒-药物相互作用。

Rapid, reliable, and sensitive assay systems for testing antiviral activity of potential drugs are essential for the development of antiviral therapy of AIDS. Multiple in vitro assay systems have now been available and these assay systems should further accelerate the identification of new antiretroviral agents. However, a number of variables or factors influence the results of the in vitro antiviral testing. Antiviral data can greatly vary depending on the target cells employed. Viral doses, viral strains, time of drug addition, duration of culture, and endpoints used can also significantly influence the antiviral data. Human peripheral blood mononuclear cells (PBM) have been frequently used as target cells following stimulation with phytohemagglutinin (PHA) for the study of activity of various drugs against HIV. PHA-stimulated PBM (PHA-PBM) may provide a milieu close to the in vivo situation and therefore may serve as one of the most suitable target cells for antiviral testing. However, it is as yet poorly understood whether the sensitivity of HIV-1 to drugs as assessed in PHA-PBM correlates with the virus-drug interactions in patients with AIDS.